Free tool
FAERS Monitor: Samsca
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022275 or its brand name (Samsca, Tolvaptan). Reports on generic versions are filed under their own applications.
Reports
14,926
Serious
11,890
80% of reports
Hospitalization
4,752
Death reported
3,255
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death1,042
- thirst1,011
- off label use888
- renal impairment884
- cardiac failure828
- product dose omission issue779
- pollakiuria602
- wrong technique in product usage process535
- product use in unapproved indication501
- underdose498
- dehydration481
- no adverse event481
- blood creatinine increased467
- inappropriate schedule of product administration460
- polyuria456
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2008 | 1 |
| 2009 | 14 |
| 2010 | 43 |
| 2011 | 128 |
| 2012 | 345 |
| 2013 | 430 |
| 2014 | 357 |
| 2015 | 531 |
| 2016 | 744 |
| 2017 | 889 |
| 2018 | 1,079 |
| 2019 | 1,238 |
| 2020 | 761 |
| 2021 | 1,018 |
| 2022 | 1,022 |
| 2023 | 1,068 |
| 2024 | 1,521 |
| 2025 | 2,027 |
| 2026 | 1,710 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,039,233 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| thirstSignal | 1,011 | 84.5 | 79.4 | 78,666 |
| polyuriaSignal | 456 | 83.0 | 75.7 | 34,837 |
| pollakiuriaSignal | 602 | 20.6 | 19.1 | 11,083 |
| renal impairmentSignal | 884 | 15.0 | 14.0 | 11,440 |
| cardiac failureSignal | 828 | 14.7 | 13.7 | 10,469 |
| blood creatinine increasedSignal | 467 | 10.1 | 9.3 | 3,825 |
| underdoseSignal | 498 | 9.7 | 8.9 | 3,851 |
| dehydrationSignal | 481 | 5.1 | 4.7 | 1,584 |
| no adverse eventSignal | 481 | 3.7 | 3.4 | 972 |
| product dose omission issueSignal | 779 | 3.7 | 3.5 | 1,579 |
| wrong technique in product usage processSignal | 535 | 3.7 | 3.4 | 1,073 |
| inappropriate schedule of product administrationSignal | 460 | 3.6 | 3.3 | 868 |
| product use in unapproved indicationSignal | 501 | 2.9 | 2.6 | 607 |
| death | 1,042 | 1.7 | 1.6 | 316 |
| off label use | 888 | 1.4 | 1.3 | 119 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.